{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:41Z","timestamp":1786118441101,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clineuro.2025.109282","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:09:03Z","timestamp":1764781743000},"page":"109282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bone modifying agents and multikinase inhibitors as treatments for chordoma: A TriNetX-based retrospective cohort study"],"prefix":"10.1016","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7703-2346","authenticated-orcid":false,"given":"Kamal","family":"Shaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3481-0808","authenticated-orcid":false,"given":"Spencer","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6313-7173","authenticated-orcid":false,"given":"Rudy","family":"Rahme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-7937","authenticated-orcid":false,"given":"Michael","family":"Karsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2025.109282_bib1","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S1470-2045(14)71190-8","article-title":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","volume":"16","author":"Stacchiotti","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib2","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1634\/theoncologist.12-11-1344","article-title":"Chordoma: the nonsarcoma primary bone tumor","volume":"12","author":"Chugh","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clineuro.2025.109282_bib4","article-title":"Clinicopathological and prognostic characteristics in dedifferentiated\/poorly differentiated Chordomas: a pooled analysis of individual patient data from 58 studies and comparison with conventional Chordomas","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib5","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/ijms25115877","article-title":"Chordoma: genetics and contemporary management","volume":"25","author":"Desai","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clineuro.2025.109282_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41379-018-0002-1","article-title":"Clinicopathologic characteristics of poorly differentiated chordoma","volume":"31","author":"Shih","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.clineuro.2025.109282_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","article-title":"Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer","volume":"76","author":"Saad","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clineuro.2025.109282_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple Myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib9","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"European J Cancer"},{"key":"10.1016\/j.clineuro.2025.109282_bib10","article-title":"Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma","volume":"4","author":"Terpos","year":"2015","journal-title":"Bone Rep."},{"key":"10.1016\/j.clineuro.2025.109282_bib11","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1016\/j.clbc.2023.08.008","article-title":"Bone-targeted therapy regimen and skeletal-related events in patients surviving longer than 2 years with metastatic breast cancer and bone metastasis","volume":"23","author":"Jayan","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.clineuro.2025.109282_bib12","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdv300","article-title":"Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF\/GETO)","volume":"26","author":"Bompas","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib13","first-page":"600","article-title":"Phase II Study of Cabozantinib in patients with bone metastasis","volume":"27","author":"Choy","year":"2022","journal-title":"Oncol. (Dayt. Ohio)"},{"key":"10.1016\/j.clineuro.2025.109282_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cam4.4983","article-title":"Use of multikinase inhibitors\/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine-resistant differentiated thyroid cancer","volume":"11","author":"Navarro-Gonzalez","year":"2022","journal-title":"Cancer Med (Malden MA)"},{"key":"10.1016\/j.clineuro.2025.109282_bib15","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/annonc\/mdt117","article-title":"Phase II study on lapatinib in advanced EGFR-positive chordoma","volume":"24","author":"Stacchiotti","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib16","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clineuro.2025.109282_bib17","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clineuro.2025.109282_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients\u2014Experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib19","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20230351","article-title":"Factors associated with quality of life in patients receiving palliative radiotherapy for bone metastases: A secondary cross-sectional analysis of data from a prospective multicenter observational study","volume":"96","author":"Saito","year":"2023","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.clineuro.2025.109282_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jmir.2020.11.014","article-title":"Pre-radiotherapy pain intensity and health-related quality of life in patients with bone metastases at various vertebral levels","volume":"52","author":"Hindle","year":"2021","journal-title":"J. Med. Imaging Radiat. Sci."},{"key":"10.1016\/j.clineuro.2025.109282_bib21","doi-asserted-by":"crossref","first-page":"e2651","DOI":"10.1210\/clinem\/dgac111","article-title":"Response to Letter to the Editor From Taguchi: \u201cOsteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clineuro.2025.109282_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.clineuro.2025.109282_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejca.2022.08.011","article-title":"RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis","volume":"175","author":"Schreuder","year":"2022","journal-title":"European journal cancer (1990)"},{"key":"10.1016\/j.clineuro.2025.109282_bib25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s13402-024-00946-6","article-title":"Chordoma cells possess bone-dissolving activity at the bone invasion front","volume":"47","author":"Kawaai","year":"2024","journal-title":"Cell. Oncol. (Dordr. )"},{"key":"10.1016\/j.clineuro.2025.109282_bib26","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.3390\/ijms26114990","article-title":"RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments","volume":"26","author":"Gkikopoulou","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clineuro.2025.109282_bib27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clineuro.2025.109282_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/08998280.2023.2276623","article-title":"Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis","volume":"37","author":"Bradley","year":"2024","journal-title":"Proc. Bayl. Univ. Med. Cent."},{"key":"10.1016\/j.clineuro.2025.109282_bib29","doi-asserted-by":"crossref","first-page":"R247","DOI":"10.1530\/ERC-12-0400","article-title":"Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies","volume":"21","author":"Alem\u00e1n","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.clineuro.2025.109282_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","article-title":"Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"17","author":"Chen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.clineuro.2025.109282_bib31","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized Trial\u2014The Zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725005657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725005657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:55:12Z","timestamp":1786031712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846725005657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S0303846725005657"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109282","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone modifying agents and multikinase inhibitors as treatments for chordoma: A TriNetX-based retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109282"}}